Sanofi announces positive data for frexalimab product to treat multiple sclerosis

PARIS (Reuters) – French healthcare company Sanofi announced on Wednesday positive data for its frexalimab product aimed at treating multiple sclerosis, and that the firm plans to initiate pivotal trials in multiple sclerosis in early 2024.

(Reporting by Sudip Kar-Gupta; Editing by Shri Navaratnam)